Boehringer posts flat earnings on stagnant Pradaxa sales
April 22, 2015 at 04:30 AM EDT
FRANKFURT, April 22 (Reuters) - Boehringer Ingelheim, Germany's second-largest drugmaker, posted 5.3 percent lower sales and flat operating profit for 2014, hurt by healthcare budget cuts in the United States and stagnant sales of stroke prevention pill Pradaxa.
